Inverted neutrino mass hierarchy and mixing in the Zee-Babu model

We show that the neutrino mass matrix of the Zee-Babu model isable to fit the recent data on neutrino masses and mixingwith non-zero $\theta_{13}$ in the inverted neutrino mass hierarchy. The results show that the Majorana  phases are equal to zero and the Dirac phase (\de) ispredicted to either $0$ or $\pi$, i. e, there is no CP violation in the Zee-Babu model at the two loop level. The effective mass governingneutrinoless double beta decay and the sum of neutrino masses areconsistent with the recent analysis

Nanomaterial for Adjuvants Vaccine: Practical Applications and Prospects

Vaccines contain adjuvants to strengthen the immune responses of the receiver against pathogen infection or malignancy. A new generation of adjuvants is being developed to give more robust antigen-specific responses, specific types of immune responses, and a high margin of safety. By changing the physical and chemical properties of nanomaterials, it is possible to make antigen-delivery systems with high bioavailability, controlled and sustained release patterns, and the ability to target and image. Nanomaterials can modulate the immune system so that cellular and humoral immune responses more closely resemble those desired. The use of nanoparticles as adjuvants is believed to significantly improve the immunological outcomes of vaccination because of the combination of their immunomodulatory and delivery effects. In this review, we discuss the recent developments in new adjuvants using nanomaterials. Based on three main vaccines, the subunit, DNA, and RNA vaccines, the possible ways that nanomaterials change the immune responses caused by vaccines, such as a charge on the surface or a change to the surface, and how they affect the immunological results have been studied. This study aims to provide succinct information on the use of nanomaterials for COVID-19 vaccines and possible new applications

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Recent Applications and Prospects of Nanowire-Based Biosensors

High-sensitivity biomedical sensors could make it possible to detect and classify chemical and biological species in a variety of applications, from disease diagnosis to medication discovery, thus, boosting the likelihood of life-saving intervention. Synthesized nanowires have already produced advancements in a variety of sectors, including biological sensors over the last decade. When compared to macro-sized materials, the nanowires’ large surface area-to-volume ratio increased sensitivity. Their applications for biomarker, viral, and DNA detection, as well as drug discovery, are also discussed. Self-powering, reusability, sensitivity in high ionic strength solvents, and long-term stability are all examples of recent developments. Shortly, the nanowire is likely to lead to major improvements in biomedical sensors. This review provides a full overview of the nanowire sensor’s working principle and production procedure. We have discussed how to produce nanowires that can be utilized as biosensors for different bacteria and pathogens, protease, DNA and RNA, neurotransmitters, and chemical compounds. Biosensing technology has dramatically improved because of the introduction of nanowires in biosensors. This is a result of the application of new biorecognition components and transducers, improvements in the manufacture, design, and miniaturization of nanostructured devices at the micron scale, and unique approaches for the synthesis of nanowires. The versatility, robustness, and dynamic nature of sensing technologies have all improved thanks to the usage of nanowires

A Facile Method for the Synthesis of a MoS2/g-C3N4 Photocatalyst

status: publishe